Hepatitis B therapy in pregnancy

被引：36

作者：

Bzowej N.H. ^{[1
]}

机构：

[1] California Pacific Medical Center, 2340 Clay Street, Suite 312, San Francisco, 94115, CA

来源：

Current Hepatitis Reports | 2010年 / 9卷 / 4期

关键词：

Antiviral; Hepatitis B; Lamivudine; Nucleoside; Nucleotide; Perinatal transmission; Pregnancy; Tenofovir; Treatment;

D O I：

10.1007/s11901-010-0059-x

中图分类号：

学科分类号：

摘要：

All decisions about initiating, continuing, or stopping therapy of the hepatitis B virus (HBV) during pregnancy must include an analysis of the risks and benefits for mother and fetus. The trimester of the pregnancy and the stage of the mother's liver disease are important factors. Treatment in the third trimester may be initiated to aid in preventing perinatal transmission, which appears to be most pronounced in mothers with high viral loads. Consideration of initiating treatment in the third trimester should occur after a high viral load is documented in the latter part of the second trimester, to allow adequate time for initiation of antiviral therapy with significant viral suppression before delivery. This discussion should include the topic of breastfeeding, because it is generally not recommended while receiving antiviral therapy. Currently, lamivudine and tenofovir appear to be the therapeutic options with the most reasonable safety data in pregnancy. © 2010 The Author(s).

引用

页码：197 / 204

页数：7

共 46 条

[1]

Hepatitis B: World Health Organization Fact Sheet 204 (Revised August 2008)

[2]

Yao G.B., Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China, Gut, 38, (1996)

[3]

Lok A.S., McMahon B.J., Chronic hepatitis B: Update 2009, Hepatology, 50, pp. 1-36, (2009)

[4]

McMahon B.J., Alward W.L., Hall D.B., Et al., Acute hepatitis B virus infection: Relation to the clinical expression of disease and subsequent development of the carrier state, J Infect Dis, 151, pp. 599-603, (1985)

[5]

Tassopoulos N.C., Papavangelou G.J., Sjogren M.H., Et al., Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults, Gastroenterology, 92, pp. 1844-1850, (1987)

[6]

Chang M.-H., Natural history of hepatitis B virus infection in children, Journal of Gastroenterology and Hepatology, 15, SUPPL. MAY, (2000)

[7]

Keeffe E.B., Dieterich D.T., Han S.B., Et al., A treatment algorithm for the management of chronic hepatitis B in the United States: 2008 update, Clin Gastroenterol Hepatol, 6, pp. 1315-1341, (2008)

[8]

Lau G.K.K., Piratvisuth T., Kang X.L., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Wan C.C., Seung W.P., Wen Y.C., Berg T., Flisiak R., McCloud P., Pluck N., Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, New England Journal of Medicine, 352, 26, pp. 2682-2695, (2005)

[9]

Marcellin P., Heathcote E.J., Buti M., Et al., Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for Chronic Hepatitis B, 359, pp. 2442-2455, (2008)

[10]

Fontana R.J., Side effects of long-term oral antiviral therapy for hepatitis B, Hepatology, 49, (2009)

← 1 2 3 4 5 →